Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29 Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Condition: Desmoplastic Melanoma Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Condition: Lung Cancer Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Brain and Central Nervous System Tumors Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group Recruiting
Condition: Multiple Sclerosis, Relapsing-Remitting Intervention: Other: Early Aggressive Therapy or Traditional Therapy Sponsors: Johns Hopkins University; Patient-Centered Outcomes Research Institute Recruiting
Conditions: Breast Carcinoma; Estrogen Receptor Negative; Progesterone Receptor Negative Interventions: Procedure: Screening Mammography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Metastatic Malignant Neoplasm in the Brain Interventions: Radiation: Single Fraction Stereotactic Radiosurgery; Radiation: Fractionated Stereotactic Radiosurgery; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Skin Squamous Cell Carcinoma; Metastatic Skin Cancer Interventions: Drug: Avelumab; Drug: Cetuximab Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Breast Cancer Stage 0; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III Interventions: Other: Usual Care; Other: Web-based decision aid Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Agency for Healthcare Research and Quality (AHRQ) Recruiting
Condition: Early Breast Cancer Interventions: Drug: Ribociclib; Other: Endocrine Therapy Sponsors: Novartis Pharmaceuticals; Translational Research in Oncology Recruiting
Condition: Non Small Cell Lung Cancer Interventions: Drug: N-803 + Pembrolizumab; Drug: Pembrolizumab Sponsors: Altor BioScience; NantCell, Inc. Recruiting
Condition: Triple Negative Breast Cancer Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Drug: Dose-dense Doxorubicin or dose-dense Epirubicin; Drug: Cyclophosphamide Sponsors: Hoffmann-La Roche; Breast International Group; Alliance Foundation Trials (AFT); Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU); Frontier Science and Technology Research Foundation Inc (FS) Recruiting
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Advanced Cancer; Metastatic Cancer Interventions: Other: Patient Self-Reporting of Symptoms; Other: Usual Care Delivery Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; University of North Carolina; Mayo Clinic; American Society of Clinical Oncology; American Cancer Society, Inc.; Dana-Farber Cancer Institute Recruiting
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI); NRG Oncology Recruiting
Condition: Heart Failure Interventions: Other: Digital Engagement; Other: Direct Engagement Sponsors: Duke University; Duke Clinical Research Institute Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: DCIS; Ductal Carcinoma in Situ Interventions: Other: Guideline Concordant Care; Other: Active Surveillance Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; Duke University; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; New York University; Washington University School of Medicine Recruiting
Condition: Multiple Myeloma in Relapse Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc. Recruiting
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group Recruiting
Conditions: Prostate Cancer Early Risk Treated by Radiosurgery; Prostate Cancer Intermediate Risk Treated by Radiosurgery Intervention: Sponsor: Florida Robotic Radiosurgery Association Recruiting